Journal of Molecular Oncology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - Journal of Molecular Oncology Research (2023) Volume 7, Issue 5

An oncolytic herpes simplex virus provides effective head and neck squamous cell carcinoma treatment.

Takashi Hoshi *

Departments of Physiology, Keio University, Tokyo, Japan

*Corresponding Author:
Takashi Hoshi
Departments of Physiology
Keio University
Tokyo, Japan

Received:28-Aug-2023, Manuscript No. AAMOR-23-112363; Editor assigned:31-Aug-2023, PreQC No. AAMOR-23-112363 (PQ); Reviewed:14-Sep-2023, QC No. AAMOR-23-112363; Revised:20-Sep-2023, Manuscript No. AAMOR-23-112363 (R); Published:27-Sep-2023, DOI:10.35841/ aamor-7.5.198

Citation: Hoshi T. An oncolytic herpes simplex virus provides effective head and neck squamous cell carcinoma treatment. J Mol Oncol Res. 2023;7(5):198

Visit for more related articles at Journal of Molecular Oncology Research


Oncolytic viruses have emerged as a promising frontier in the fight against this difficult illness in the never-ending search for novel cancer medicines. These extraordinary biological agents, which were long primarily thought of as infections, are now being used for their capacity to target and eradicate cancer cells with precision while preserving healthy tissue. The development of novel, targeted therapy using oncolytic viruses, which combine the fields of virology and oncology, offers new hope for patients dealing with a variety of cancers [1].

Given the few therapy choices and frequently fatal consequences for Head and Neck Squamous Cell Carcinoma (HNSCC), it is difficult to treat. Oncolytic virotherapy, however, has recently made strides that have given those battling this aggressive form of cancer fresh hope. A possible game-changer in the fight against HNSCC has emerged from among these promising developments: an oncolytic Herpes Simplex Virus (oHSV) [2].

The term "HNSCC" refers to a group of malignancies that start in the salivary glands, mouth, throat, nose, and other mucous membranes in the head and neck area. This type of cancer is infamous for being extremely aggressive and frequently leading to severe functional disability and deformity. Use of tobacco, drinking, and being exposed to the human papillomavirus (HPV) are the main risk factors. Chemotherapy, radiation therapy, and surgery are common forms of treatment for HNSCC. Although these methods can be somewhat successful, they frequently have crippling side effects and may not produce satisfying results, especially when the condition is advanced [3].

A group of viruses known as oncolytic viruses are genetically altered or naturally occurring viruses that only attack and multiply in cancer cells, sparing normal tissue. Among them, the Herpes Simplex Virus (HSV) has demonstrated excellent promise for the treatment of HNSCC. Due to its inherent preference for infecting mucosal cells, which are prevalent in the head and neck region, HSV is well suited for this usage [4].

The effectiveness of oHSV in treating HNSCC has been proven in a number of clinical trials. A modified oHSV was used by researchers in one significant study that was published in the journal "Science Translational Medicine," and the findings were truly astounding. Significant tumor shrinking was observed in patients who had tried all conventional therapy methods, and some even managed to achieve complete remission. Additionally, oHSV therapy has a special benefit in that it might make the immune system more sensitive to the presence of cancer cells. This may improve the efficacy of other immune-based treatments such checkpoint inhibitors, which have potential for treating HNSCC [5].


The use of oncolytic herpes simplex virus therapy in the management of head and neck squamous cell carcinoma is a novel strategy. It gives individuals dealing with this difficult diagnosis unexpected hope thanks to its capacity to target and eliminate cancer cells selectively while triggering the immune system.


  1. Harrington KJ, Puzanov I, Hecht JR, et al. Clinical development of talimogene laherparepvec (T-VEC): A modified herpes simplex virus type-1–derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015;15(12):1389-403.
  2. Indexed at, Google Scholar, Cross Ref

  3. Goebel EA, Davidson BL, Graham SM, et al. Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 1998;119(4):331-6.
  4. Indexed at, Google Scholar, Cross Ref

  5. Campadelli?Fiume G, De Giovanni C, Gatta V, et al. Rethinking herpes simplex virus: The way to oncolytic agents. Rev. Med. Virol. 2011;21(4):213-26.
  6. Indexed at, Google Scholar, Cross Ref

  7. Jarnagin WR, Zager JS, Klimstra D, et al. Neoadjuvant treatment of hepatic malignancy: An oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Canc gene therapy. 2003;10(3):215-23.
  8. Indexed at, Google Scholar, Cross Ref

  9. Fuereder T. Immunotherapy for head and neck squamous cell carcinoma. Memo Mag Eur Med Oncol Ezoic. 2016;9:66-9.
  10. Google Scholar

Get the App